News & Updates

Patients with de novo human epidermal growth receptor 2 (HER2)-positive metastatic breast cancer (MBC) who show radiographic response to first-line HER2-directed therapy are more likely to achieve long-term survival, suggests a recent study.

Use of either stereotactic body radiotherapy (SBRT) or yttrium-90 (Y90) is effective in the management of hepatocellular carcinoma (HCC), resulting in similar overall and progression-free survival, reports a study. However, Y90 is more expensive than SBRT.

The rates of breast cancer-related lymphedema (BCRL) in Singapore are similar to those across the globe, reports a Singapore study. In addition, the findings also stress the comparable profiles of patients who are vulnerable to the disease.

A weight management intervention results in better body composition, quality of life, and prostate cancer (PCa) biomarkers in men scheduled for prostatectomy, reports a study.

Adding bevacizumab to an EGFR tyrosine kinase inhibitor (TKI) improves overall survival (OS) in adult patients with EGFR-mutated non-small-cell lung cancer (NSCLC) and leptomeningeal metastases (LMs), according to a single-centre, retrospective, real-world study in China. OS was, however, similar between patients on chemotherapy plus EGFR-TKI and those on EGFR-TKI monotherapy.

Clinical outcomes within 1 year of MR-guided stereotactic body radiation therapy (MRgSBRT) with rectal spacer for patients with localized prostate cancer (PC) show excellent tolerability, minimal gastrointestinal (GI) toxicity as well as improved rectal sparing and target coverage vs a non-spacer comparison cohort.

Breast cancer–specific mortality (BCSM) risk remains high over 20 years in men with stage I─III hormone receptor (HR)–positive breast cancer and the kinetics are different from those seen in women, a population-based study has shown.